Guessing
no more

News

Find here information about MNM and people we work with. In this section, we showcase about events and our achievements.

Greetings from ECML PKDD 2022!

Maciej Piernik presented one of our core algorithms at the European Conference on Machine Learning and Principles and Practice of Knowledge Discovery in Databases.

No items found.

MNM at the ESMO 2022 Congress

At ESMO 2022 Congress in Paris the era of AI deployment continues.

No items found.

Distribution-based feature extraction from copy number and structural variants in whole-genome data

With entire genomes at hand, scientists can pinpoint DNA fragments responsible for different cancers and predict patient responses to cancer treatments. However, the sheer volume of whole-genome data makes it difficult to encode the characteristics of genomic variants as features for machine learning algorithms.

No items found.

MNM's platform ARETE works!

MNM's platform ARETE - a proprietary AI technology designed for cancer genomics has been successfully externally validated by one of our Partners.

No items found.

“Random similarity forests” has been accepted at ECML PKDD 2022

We are very happy to announce that our abstract and related publication titled “Random similarity forests” has been accepted at this year’s European Conference on Machine Learning and Principles and Practice of Knowledge Discovery in Databases- #ECMLPKDD2022!

No items found.

Krzysztof Bokiej is a speaker at Data Science Summit ML Edition

Krzysztof Bokiej - Head of Platform and Pipelines at MNM - is a speaker at the most important Machine Learning conference in Poland.

No items found.

MNM Bioscience joins ESMO Breast Cancer 2022

Breast cancer (BC) constitutes the most common female malignancy and nowadays molecular classification of subtypes is crucial to estimate a patient’s prognosis and administer appropriate treatment. It allows tailoring therapeutic strategy much more precisely than using a standalone IHC status.

No items found.

MNM Bioscience eyes cancer drug target discovery based on its AI algorithms

MNM Bioscience began as a bioinformatics company that curates data and then builds artificial intelligence-based algorithms, but it is now looking to branch out into oncology drug target discovery.

No items found.

5th DNA Repair/Replication Structures and Cancer Conference

MNM Bioscience presents its participation in the fifth DNA Repair/Replication Structures & Cancer conference (27 Apr 2022 – 01 May 2022), where speakers will focus on presenting the structural and mechanistic insights of dynamic complexes, operating in DNA repair and replication, transcription and other cancer-relevant events.

No items found.

MNM Bioscience received $800 000 funding through Eureka Eurostars for our newest project

We are thrilled to announce that MNM Bioscience received $800 000 funding through Eureka Eurostars for our newest project.

No items found.